Mostrar el registro sencillo del ítem

Beta-lactam and aminoglycoside resistance rates and mechanisms among Pseudomonas aeruginosa in French general practice (community and private healthcare centres).

dc.rights.licenseopenen_US
hal.structure.identifierMicrobiologie Fondamentale et Pathogénicité [MFP]
dc.contributor.authorDUBOIS, Véronique
dc.contributor.authorARPIN, Corinne
IDREF: 093324626
dc.contributor.authorDUPART, Virginie
dc.contributor.authorSCAVELLI, Aline
dc.contributor.authorCOULANGE, Laure
dc.contributor.authorANDRÉ, Catherine
dc.contributor.authorFISCHER, Isabelle
dc.contributor.authorGROBOST, Frédéric
dc.contributor.authorBROCHET, Jean-Philippe
dc.contributor.authorLAGRANGE, Isabelle
dc.contributor.authorDUTILH, Brigitte
dc.contributor.authorJULLIN, Jacqueline
dc.contributor.authorNOURY, Patrick
dc.contributor.authorLARRIBET, Gilberte
dc.contributor.authorQUENTIN, Claudine
dc.date.accessioned2024-10-19T10:34:05Z
dc.date.available2024-10-19T10:34:05Z
dc.date.issued2008-08-01
dc.identifier.issn1460-2091en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/202592
dc.description.abstractEnThe aim of this study was to assess antibiotic resistance rates and mechanisms of beta-lactam and aminoglycoside resistance among isolates of Pseudomonas aeruginosa isolated in the extra-hospital setting (community and private healthcare centres). During a 4 month period, 226 non-repetitive strains of P. aeruginosa were collected from patients residing in private healthcare centres (73.5%) or at home (26.5%). Resistance rates were evaluated by MIC determination, and beta-lactam and aminoglycoside resistance was analysed by phenotypic tests, PCR amplification, cloning and sequencing. Among the ticarcillin-resistant strains (38.1%), 33.7% overexpressed their chromosomal cephalosporinase, 27.9% produced acquired penicillinases (21 PSE-1, 2 OXA-21 and 1 TEM-2), 4.7% produced extended-spectrum beta-lactamases (ESBLs) (3 TEM-21 and 1 SHV-2a) and 45.3% possessed a non-enzymatic resistance (NER). Thus, 88.4% had a single mechanism of resistance, whereas 11.6% cumulated several mechanisms. No carbapenemases were detected among the 6.6% imipenem-resistant strains. With regard to aminoglycosides, 23.0% of the strains exhibited an acquired resistance to gentamicin (GEN), tobramycin (TOB), amikacin (AMK) or netilmicin (NET). Enzymatic resistance was more frequent (71.2%) than NER (34.6%). Various aminoglycoside modifying enzymes were associated with overlapping phenotypes: 36.5% strains produced AAC(6')-I with either a serine (GEN-TOB-NET) or a leucine (TOB-NET-AMK) at position 119, or both variants (GEN-TOB-NET-AMK); 21.2% expressed ANT(2'')-I (GEN-TOB), 7.7% AAC(3)-II (GEN-TOB-NET), 5.8% AAC(3)-I (GEN) and 1.9% AAC(6')-II (GEN-TOB-NET-AMK) or AACA7 (TOB-NET-AMK). Antibiotic resistance rates in P. aeruginosa were globally similar in general practice as in French hospitals. This first analysis of resistance mechanisms showed an unexpectedly high frequency of ESBLs and an unusual distribution of aminoglycoside modifying enzymes.
dc.language.isoENen_US
dc.subject.enAcetyltransferases
dc.subject.enAdolescent
dc.subject.enAdult
dc.subject.enAged
dc.subject.enAged
dc.subject.en80 and over
dc.subject.enAminoglycosides
dc.subject.enAnti-Bacterial Agents
dc.subject.enBacterial Proteins
dc.subject.enChild
dc.subject.enChild
dc.subject.enPreschool
dc.subject.enCommunity Health Centers
dc.subject.enCommunity-Acquired Infections
dc.subject.enDNA
dc.subject.enBacterial
dc.subject.enDrug Resistance
dc.subject.enBacterial
dc.subject.enFemale
dc.subject.enFrance
dc.subject.enHumans
dc.subject.enInfant
dc.subject.enInfant
dc.subject.enNewborn
dc.subject.enMale
dc.subject.enMicrobial Sensitivity Tests
dc.subject.enMiddle Aged
dc.subject.enNucleotidyltransferases
dc.subject.enPolymerase Chain Reaction
dc.subject.enPseudomonas Infections
dc.subject.enPseudomonas aeruginosa
dc.subject.enSequence Analysis
dc.subject.enDNA
dc.subject.enbeta-Lactamases
dc.subject.enbeta-Lactams
dc.title.enBeta-lactam and aminoglycoside resistance rates and mechanisms among Pseudomonas aeruginosa in French general practice (community and private healthcare centres).
dc.title.alternativeJ Antimicrob Chemotheren_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1093/jac/dkn174en_US
dc.subject.halSciences du Vivant [q-bio]/Microbiologie et Parasitologieen_US
dc.identifier.pubmed18467306en_US
bordeaux.journalJournal of Antimicrobial Chemotherapyen_US
bordeaux.page316-23en_US
bordeaux.volume62en_US
bordeaux.hal.laboratoriesMFP (Laboratoire Microbiologie Fondamentale et Pathogénicité) - UMR 5234en_US
bordeaux.issue2en_US
bordeaux.institutionCNRSen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcepubmed
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exportfalse
workflow.import.sourcepubmed
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Journal%20of%20Antimicrobial%20Chemotherapy&rft.date=2008-08-01&rft.volume=62&rft.issue=2&rft.spage=316-23&rft.epage=316-23&rft.eissn=1460-2091&rft.issn=1460-2091&rft.au=DUBOIS,%20V%C3%A9ronique&ARPIN,%20Corinne&DUPART,%20Virginie&SCAVELLI,%20Aline&COULANGE,%20Laure&rft.genre=article


Archivos en el ítem

ArchivosTamañoFormatoVer

No hay archivos asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem